在圣劳伦斯河及其主要支流的表面水中追踪制药污染
Marc-Antoine Vaudreuil1, Gabriel Munoz1, Sung Vo Duy1
1Department of Chemistry, Université de Montréal, Montréal, QC, Canada.
The Science of the total environment
|November 23, 2023
概括
咖啡因,狄克洛菲纳克和文拉法辛等药物在圣劳伦斯河流域普遍存在. 高度,特别是蒙特利尔的下游,对水生生物构成风险.
科学领域:
- 环境化学环境化学
- 生态毒理学 生态毒理学
- 评估水质水质的评估.
背景情况:
- 在全球范围内,在水生环境中越来越多地检测到药品.
- 废水处理厂是制药污染的主要来源.
- 了解药品的分布和生态影响对于水资源管理至关重要.
研究的目的:
- 评估在圣劳伦斯河及其支流中27种药品和代谢物的发生和空间分布.
- 评估检测到的药物度所带来的潜在生态风险.
- 确定流域中制药污染的主要来源和途径.
主要方法:
- 在五年 (2017-2021) 时间内对地表水,深水和沉积物样本进行侦察调查.
- 分析了406个样本,这些样本是在圣劳伦斯河和55条支流的700公里范围内收集的.
- 使用淡水预测无效度 (PNEC) 的地理绘图,统计分析和风险系数方法.
主要成果:
- 咖啡因,迪克洛菲纳克和文拉法辛是最频繁检测到的药物 (>80%的检测率).
- 在市政废水污水附近发现了极高度的布洛芬,基布洛芬和咖啡因.
- 蒙特利尔下游的圣劳伦斯河的污染量显著增加,扩展至70公里,这是五年来的一贯趋势.
- 蒙特利尔大区 (Mascouche,Saint-Régis,Bertrand) 的附属企业表现出最高的制药水平.
- 确定了Des Prairies,Saint-François,Richelieu,Ottawa和Yamaska河流是制药量负载的主要贡献者.
- 四种化合物 (咖啡因,卡巴马泽平,狄克洛芬,易布洛芬) 对水生生物有中高风险.
结论:
- 城市废水,特别是来自蒙特利尔的废水,是圣劳伦斯河中制药污染的重要来源.
- 制药污染是流域中持续存在的问题,具有潜在的生态后果.
- 需要有效的管理策略来减轻制药投入和保护水生生态系统.
更多相关视频
相关概念视频
Primary Production
23.6K
The total amount of energy acquired by primary producers in an ecosystem is called gross primary production (GPP). However, of this energy, producers use some for metabolic processes, and some is lost as heat, decreasing the amount of energy available to the next trophic level. The remaining usable amount of energy is called the net primary productivity (NPP). In terrestrial ecosystems, NPP is driven by climate, while light penetration and nutrient availability drive NPP in aquatic ecosystems.
23.6K
Pharmacovigilance
857
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
857


